U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07024212) titled 'Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects' on April 24.
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II clinical trial that consists of two parts. The primary objective of Part 1 is to assess the preliminary efficacy of DR10624 Injection in MASLD subjects at high risk of liver fibrosis. The secondary objectives are to assess the safety and tolerability, PK profiles, and immunogenicity of DR10624 Injection in these subjects. The exploratory objectives are to assess the efficacy of DR10624 Injection in these subjects ...